Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 27, 2026
TickeronGET DAILY SIGNALS
Chemed (CHE) Delivers Solid Q3 2026 Results with +10.6% Revenue Growth

Chemed (CHE) Delivers Solid Q3 2026 Results with +10.6% Revenue Growth

Key Takeaways

  • Chemed reported third-quarter 2026 revenue of $690.9 million, up 10.6% from $624.9 million a year earlier.
  • Adjusted (non-GAAP) earnings per share (EPS) came in at $6.75, beating the consensus estimate of $6.44 by about 4.9%.
  • GAAP (Generally Accepted Accounting Principles) diluted EPS rose 22.2% to $5.45, from $4.46 in the prior-year quarter.
  • The VITAS hospice segment drove results with 12.2% revenue growth, while the Roto-Rooter segment grew revenue 7.5%.
  • Management said full-year 2026 adjusted EPS is expected to be at or slightly above the high end of prior guidance.

Earnings Context and Why It Matters

Chemed Corporation runs two very different businesses: VITAS, one of the largest hospice care providers in the United States, and Roto-Rooter, a leading plumbing and drain-cleaning franchise. This combination gives quarterly results a window into both healthcare demand and consumer spending on home repairs. Ahead of the report, the focus was on whether VITAS could maintain its patient census momentum and whether Roto-Rooter could continue expanding in a softer consumer environment. The quarter also included a strategic move, as Chemed re-acquired California franchise territories for Roto-Rooter, which changes the segment’s operating footprint going forward.

Reported Results

For the quarter ended September 30, 2026, Chemed posted service revenues and sales of $690.9 million, a 10.6% increase from $624.9 million in the same period last year. The figure came in modestly above analyst consensus estimates of roughly $684.5 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

On a GAAP basis, net income reached $71.6 million, with diluted EPS of $5.45, up 22.2% from $4.46 a year ago. Adjusted (non-GAAP) EPS was $6.75, beating the consensus estimate of $6.44 by approximately 4.9%. Adjusted EBITDA came in at $133.8 million, slightly above the $130.9 million projected by analysts, producing an adjusted EBITDA margin of 19.4%.

Both segments contributed. VITAS revenue increased 12.2% to $457.4 million, helped by a 9.4% rise in average daily census to 24,428 patients and a 7.2% increase in admissions to 18,995. Roto-Rooter revenue grew 7.5% to $233.5 million, with operating margin improving to 14% from 12% in the prior-year quarter.

Market Reaction and Investor Sentiment

Following the release, shares of CHE traded in a relatively narrow range near $505 to $509 in after-hours and pre-market activity. The measured response suggests investors had already anticipated continued strength at VITAS, although the earnings and revenue beats plus the positive full-year commentary reinforced the growth outlook. Over the past three months the stock had eased modestly, while the 12-month return remained positive. The main driver of sentiment appeared to be the sustainability of VITAS patient census growth and the raised full-year adjusted EPS guidance.

Forward Outlook and Key Factors to Monitor

Management indicated that full-year 2026 adjusted EPS should come in at or slightly above the high end of the July guidance range. This points to continued operating momentum through the fourth quarter, supported by demand in hospice care and steady activity at the plumbing segment.

Investors will want to track VITAS average daily census and admission trends, as these remain the core drivers of hospice revenue and can be influenced by labor availability, regulatory shifts, and Medicare reimbursement policy. Capacity expansion and clinician hiring will be important for maintaining double-digit segment growth.

On the Roto-Rooter side, the re-acquisition of California franchise territories for roughly $62.5 million represents a notable change that brings direct operating responsibility and may affect near-term margins during integration. Consumer spending on discretionary home repairs is another variable worth watching.

Capital allocation will also stay in focus. Chemed repurchased 125,000 shares for $66.0 million during the quarter, and further buybacks alongside franchise acquisitions and any debt moves will likely draw attention.

Exploring AI Tools for Stock Analysis

In my own research process, I frequently rely on Tickeron’s AI Screener to quickly filter for comparable names and monitor technical and fundamental signals across the market. The tool allows me to set custom criteria around industry, performance, and volatility, which helps surface ideas that might otherwise take longer to identify manually. For anyone following CHE, it provides a practical way to keep tabs on peers and evolving conditions without replacing traditional fundamental work.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CHE

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CHE's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for CHE moved out of overbought territory on October 30, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 instances where the indicator moved out of the overbought zone. In 20 of the 37 cases the stock moved lower in the days that followed. This puts the odds of a move down at 54%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CHE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 48%.

CHE broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 19, 2026. You may want to consider a long position or call options on CHE as a result. In 48 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 51%.

CHE moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for CHE crossed bullishly above the 50-day moving average on October 28, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 57%.

Following a +2.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where CHE advanced for three days, in 160 of 320 cases, the price rose further within the following month. The odds of a continued upward trend are 50%.

The Aroon Indicator entered an Uptrend today. In 69 of 198 cases where CHE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 35%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 26 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 36 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. CHE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Profit vs. Risk Rating rating for this company is 67 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CHE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock better than average.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.310) is normal, around the industry mean (204.532). P/E Ratio (26.549) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (1.876) is also within normal values, averaging (2.498). Dividend Yield (0.005) settles around the average of (0.153) among similar stocks. P/S Ratio (2.714) is also within normal values, averaging (2.688).

Notable companies

The most notable companies in this group are DaVita (NYSE:DVA), Community Health Systems (NYSE:CYH), WW International Inc (NASDAQ:WW).

Industry description

Hospital/Nursing Management companies own and operate health care facilities. Their operations include nursing homes, acute care facilities, retirement centers and outpatient surgery centers. HCA Healthcare Inc., Alcon Inc. and Universal Health Services, Inc. are some major companies in this industry. Technology has been at the forefront of development of advanced solutions, including quicker diagnoses of complex conditions. Investments in new diagnostics, healthcare IoT, and other healthcare technologies continue to gather momentum in this industry.

Market Cap

The average market capitalization across the Hospital/Nursing Management Industry is 5.37B. The market cap for tickers in the group ranges from 20.9K to 107.17B. HCA holds the highest valuation in this group at 107.17B. The lowest valued company is NMMCF at 20.9K.

High and low price notable news

The average weekly price growth across all stocks in the Hospital/Nursing Management Industry was -12%. For the same Industry, the average monthly price growth was -12%, and the average quarterly price growth was 0%. CHE experienced the highest price growth at 0%, while NIVF experienced the biggest fall at -88%.

Volume

The average weekly volume growth across all stocks in the Hospital/Nursing Management Industry was 13%. For the same stocks of the Industry, the average monthly volume growth was 102% and the average quarterly volume growth was 58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 52
P/E Growth Rating: 49
Price Growth Rating: 59
SMR Rating: 66
Profit Risk Rating: 83
Seasonality Score: -4 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding medical company

Industry HospitalNursingManagement

Industry
Medical Or Nursing Services
Address
255 East Fifth Street
Phone
+1 513 762-6690
Employees
15811
Web
https://www.chemed.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.